menu
    • menu

    Company profile for Biond Biologics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biond is an Israeli biotechnology discovery and development company. Our vision is to be a leading drug discovery company, developing innovative breakthrough immuno-therapies to address unmet clinical needs using our extensive scientific know-how and hands-on drug development expertise.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biond BiologicsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Misgav Industrial Park
    Telephone
    Telephone
    +972-4-8844337
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biondbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biond-biologics-ltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biond Biologics Start Ph 2 Study Of BND-22 With Anti-PD-1 Therapy
    Biond Biologics Start Ph 2 Study Of BND-22 With Anti-PD-1 Therapy

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biond-biologics-announces-initiation-of-a-phase-2-study-of-bnd-22-in-combination-with-anti-pd-1-therapy-302578137.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share
    Sanofi passes $125M ILT2 asset back to Biond Biologics
    Sanofi passes $125M ILT2 asset back to Biond Biologics

    27 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-bounces-phase-2-ilt2-asset-back-biond-biologics-after-125m-bet

    FIERCE BIOTECH
    27 Feb 2025
    Share Share
    Biond Biologics Announces Trial Collaboration With Merck KGaA
    Biond Biologics Announces Trial Collaboration With Merck KGaA

    29 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biond-biologics-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-to-evaluate-bnd-35-in-combination-with-cetuximab-in-a-phase-1-clinical-study-in-patients-with-solid-tumors-302289903.html

    PR NEWSWIRE
    29 Oct 2024
    Share Share
    Biond Biologics Doses First Patient With BND-35 In Phase 1 Clinical Trial
    Biond Biologics Doses First Patient With BND-35 In Phase 1 Clinical Trial

    24 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biond-biologics-announces-first-patient-dosed-with-bnd-35-in-phase-1-clinical-trial-302180049.html

    PR NEWSWIRE
    24 Jun 2024
    Share Share
    Biond Announces Presentation of BND-35, Anti-ILT3 Antibody at the AACR
    Biond Announces Presentation of BND-35, Anti-ILT3 Antibody at the AACR

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biond-biologics-announces-presentation-of-bnd-35-a-novel-anti-ilt3-antibody-for-remodeling-the-tumor-microenvironment-at-the-american-association-for-cancer-research-aacr-2024-annual-meeting-302099399.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share
    Biond Biologics Announces First Patients Dosed with BND-22 in PI Trial
    Biond Biologics Announces First Patients Dosed with BND-22 in PI Trial

    23 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/biond-biologics-announces-first-patients-dosed-with-bnd-22-sar444881-combinations-in-phase-1-clinical-trial-301552737.html

    PRNEWSWIRE
    23 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search